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Interplay of histidine residues 
of the Alzheimer’s disease Aβ 
peptide governs its Zn-induced 
oligomerization
Andrey N. Istrate1,*, Sergey A. Kozin1,*, Sergey S. Zhokhov2, Alexey B. Mantsyzov2, 
Olga I. Kechko1, Annalisa Pastore3, Alexander A. Makarov1 & Vladimir I. Polshakov2
Conformational changes of Aβ peptide result in its transformation from native monomeric state to the 
toxic soluble dimers, oligomers and insoluble aggregates that are hallmarks of Alzheimer’s disease 
(AD). Interactions of zinc ions with Aβ are mediated by the N-terminal Aβ1–16 domain and appear to 
play a key role in AD progression. There is a range of results indicating that these interactions trigger 
the Aβ plaque formation. We have determined structure and functional characteristics of the metal 
binding domains derived from several Aβ variants and found that their zinc-induced oligomerization is 
governed by conformational changes in the minimal zinc binding site 6HDSGYEVHH14. The residue H6 
and segment 11EVHH14, which are part of this site are crucial for formation of the two zinc-mediated 
interaction interfaces in Aβ. These structural determinants can be considered as promising targets for 
rational design of the AD-modifying drugs aimed at blocking pathological Aβ aggregation.
According to the amyloid hypothesis, which has been the predominant framework for Alzheimer disease (AD) 
studies, Aβ aggregation has a unique and critical role as an initiator of AD pathology1,2. What triggers Aβ aggre-
gation still remains unclear, however, some genetically and/or post-translationally modified Aβ species accu-
mulated in the amyloid plaques appear to act as the pathogenic aggregation seeds3. It has been shown in animal 
models of AD that zinc ions might play a crucial role in the Aβ plaque formation in vivo4–7. Indeed, at concen-
tration as high as that detected in the synapse, zinc ions specifically bind Aβ and are able to facilitate Aβ aggre-
gation8, which could explain abnormally high levels of zinc ions within amyloid plaques of AD patients9,10. It is 
assumed that zinc ions promote Aβ aggregation via population shift of polymorphic states11 with a mechanism 
similar to that observed for larger zinc-binding proteins12. When zinc-induced Aβ amyloidogenesis is observed 
in vitro, conformational changes in Aβ are also identified13. However, precise structural details of these changes 
were elusive since three-dimensional structures of Aβ oligomers complexed with zinc ions were unavailable14.
Interaction of Zn2+ with monomeric Aβ species is mediated by the metal binding domain which comprises 
the N-terminal region 1–16 of Aβ 15–17. Aβ 1–16 exists in health and disease as a separate entity18, suggesting its pos-
sible role as the structural and functional unit of the full-length Aβ . Indeed, the interaction of N-terminal region 
1–16 with the β -strand hydrophobic region 17- 42 is negligible in the model amyloid aggregates19,20, and also 
synthetic peptides Aβ 1–16 exhaustively simulate the metal binding properties of Aβ 15,16,21. Previous NMR studies 
of the N-terminus of Aβ showed that the first 9 residues are poorly structured, whereas residues beyond 10 form 
a distinct local conformation17,22–30. Structure of the tethered N-terminus of the Alzheimer’s disease amyloid-β 
peptide obtained using X-ray crystallography31 showed that Aβ region 10–16 is relatively rigid and adopts a mix-
ture of the local polyproline II-helix (PPII) and turn type conformations. The fragment Aβ 1–16 includes several 
charged residues with their location typical of ionic self-complementary peptides32. These residues participate 
in the formation of electrostatic contacts, which can stabilize both intra and intermolecular interactions. The 
region 10–16 of Aβ appeared to be an effective metal ion trapping unit33. The fragment 6–14 of Aβ has been 
determined as the minimal Zn2+ binding site wherein the ion is coordinated by H6, E11, H13, and H1434. Under 
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physiological conditions in the presence of Zn2+ the metal binding domains of several natural Aβ variants form 
homo- and hetero-dimeric complexes35–38. Residues 11–14 of the two interacting subunits compose the dimer 
interface wherein two pairs of E11 and H14 residues coordinate a zinc ion36,38.
Along with the intact Aβ isoforms which are heterogenous at their N-termini and/or C-termini, the amyloid 
plaques involve a variety of chemically modified Aβ variants39. The Aβ species extracted from the plaques can 
initiate pathological aggregation of endogenous Aβ upon intracerebral injections into animal models of AD3,40,41. 
Several post-translational modifications have been discovered to increase the aggregation rate of Aβ 42. Some 
chemical modifications and amino acid changes within the metal binding domain of Aβ (e.g. isomerization of 
D7, phosphorylation of S8, and the H6R English familial mutation associated with early onset AD) facilitate 
zinc-dependent dimerization and/or oligomerization of the domain36,38,43, thus suggesting their potential role in 
initiating the pathological aggregation process. Indeed, peripheral injections of the synthetic Aβ species bearing 
isomerized D7 (isoD7-Aβ ) was shown to trigger cerebral amyloidosis in vivo44. Little is known about the Aβ metal 
binding sites in the aggregated state (oligomers or fibrils), but in general, it seems that the binding sites are similar 
to those in the monomeric peptide11,45.
In the current study, we have used high resolution NMR spectroscopy to reveal the structural determinants 
of zinc-induced Aβ oligomerization, i.e. the structure elements that are responsible for the ability of Aβ to form 
zinc-bound intermolecular complexes. Synthetic peptides corresponding to the metal binding domains of the 
intact Aβ (Aβ 1–16), of the English H6R Aβ mutant (H6R-Aβ 1–16), Aβ containing isomerized D7 (isoD7-Aβ 1–16) 
and several truncated and mutant forms of these peptides have been used as experimental models (Fig. 1). 
Solution structure of the zinc-bridged H6R-Aβ 1–16 dimer has been determined. This structure provides direct 
information on the primary zinc-mediated Aβ dimer interface, formed by the residues 11EVHH14. The role of 
residues H6 and H13 in the emergence of the second Zn2+-dependent interface within the interacting metal 
binding domains Aβ 1–16 and isoD7-Aβ 1–16 during their zinc-induced oligomerization has been also revealed. 
Taken together, the data indicate that interplay of histidine residues in the minimal zinc-binding site 6–14 of 
Aβ upon its interactions with zinc ions underlies critical conformational changes of Aβ , which in turn lead to 
Aβ dimerization, oligomerization and aggregation. The results provide structural basis for rational design of the 
AD-modifying drugs aimed at blocking pathological Aβ aggregation.
Results
NMR signal assignments. Earlier we reported chemical shift assignments of Аβ 1–1617 and H6R-Аβ 1–1636. 
1H, 13C and 15N chemical shifts of the peptides isoD7-Аβ 1–16, isoD7-Аβ 1–10, isoD7-H13R-Аβ 1–16, Аβ 6–16 and their 
complexes with Zn2+ ions have been assigned by analysis of the set of 2D homonuclear (NOESY, ROESY, TOCSY, 
DQF-COSY) and heteronuclear (13C-1H HSQC and 15N-1H HSQC) NMR experiments. Heteronuclear spectra 
(Figs S1–S4) have been acquired at the natural abundance of 13C and 15N isotopes. In the case of isoD7-Аβ 1–16, 
isoD7-H13R-Аβ 1–16 and Аβ 6–16 15N resonance assignments have been obtained for the free peptides only, as sub-
stantial zinc-induced signal broadening does not allow collection of heteronuclear correlation spectra at the natu-
ral abundance of 15N. Resonance assignments for nearly all 1H and 13C nuclei have been determined for all studied 
peptides and their zinc complexes (Tables S1–S7).
Structure of the metal binding domains Аβ1–16, H6R-Аβ1–16 and isoD7-Аβ1–16 in free state in 
solution. Structures of the peptides Аβ 1–16, H6R-Аβ 1–16 and isoD7-Аβ 1–16 in free state in solution is virtually 
identical, as shown by the NMR spectra of the peptides measured in the absence of zinc ions (Fig. 2, Figs S5 and 
S6). Despite the fact that the peptides are relatively flexible, as evidenced by their narrow lines in NMR spectra, 
several distinct cross peaks detected in NOESY spectra indicate that the dominant backbone conformation in 
the region of residues 10–15 is close to the left-handed polyproline-II helix, observed in the crystal structure 
of Аβ 1–1631. NOEs between amide protons of neighboring residues HNi-HNi−1 and between amide protons and 
Hα (HNi-Hα i−1, HNi-Hα i−2, HNi-Hα i+1, Figs S5 and S6) confirm such dominant conformation of the fragment 
10–15. Proximity of methyl groups of the residue V12 to the side chains of Y10 and H14 (Fig. 2), observed in 
all three investigated peptides should also be noted. Thus, the fragment 10–15 in all three peptides has the same 
dominant structure, which can determine zinc-trapping properties of the metal binding domain.
Figure 1. Amino acid sequences of the studied Аβ fragments. 
www.nature.com/scientificreports/
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Aggregation states of H6R-Аβ1–16, isoD7-Аβ1–16 and Аβ6–16 in the presence of zinc ions. 
The peptides behave differently in the presence of Zn2+. Addition of equimolar amounts of zinc ions to the 
peptides isoD7-Аβ 1–16, Аβ 6–16 and Аβ 1–16 resulted in precipitation of the peptides in contrast to H6R-Аβ 1–16, 
which remained in solution in the studied concentration range (up to ~10 mM). These observations show that 
isoD7-Аβ 1–16, Аβ 6–16 and Аβ 1–16 undergo zinc-induced oligo- and/or polymerization. The precipitated peptides 
dissolve in acidic conditions (pH< 4), but precipitate again upon the increase of pH above ~6. Such pH depend-
ence indicates involvement of histidine residues in zinc binding. Precipitation of isoD7-Аβ 1–16 has been observed 
at peptide concentration above ~0.3 mM, Аβ 6–16 above ~0.8 mM and Аβ 1–16 above ~5 mM (Table 1). DLS studies 
evidence the presence of soluble zinc-induced oligomers during precipitation of the peptides (Table 1). These 
data indicate that soluble zinc-induced oligomers precede insoluble aggregates. NMR studies of the interaction 
of isoD7-Аβ 1–16 and Аβ 6–16 with Zn2+ ions have been carried out at concentration below ~0.3 mM, where both 
peptides remain soluble.
Addition of Zn2+ ions to all studied peptides leads to substantial line broadening of the NMR signals (Fig. 
S7). The nature of the peptide signal broadening primarily is associated with the exchange between multiple 
conformational states of the complex46–48. Potentially the aggregation processes can also cause signal broadening. 
However, the extent of line broadening for peptide H6R-Аβ 1–16 that never aggregated, and the peptides that aggre-
gate is virtually the same. This means that aggregation does not affect NMR line widths of these peptides under 
the given conditions. Additionally, an extra set of resonances (Figs 3 and 4, S2 and S3, S8) has been found in NMR 
spectra of the peptides Аβ 1–16, H6R-Аβ 1–16, isoD7-Аβ 1–16 and Аβ 6–16 in the presence of zinc ions. This set has been 
assigned to the dimeric peptide complexes (see below).
Figure 2. Fragments of NOESY spectra (mixing time 250 ms) of free peptides (a) Аβ 1–16, (b) H6R-Аβ 1–16, and 
(c) isoD7-Аβ 1–16 illustrating similar patterns of sequential and medium-range NOEs with the participation of 
the methyl groups of V12. Spectra were recorded in 90% H2O/10% D2O, in presence of 10 mM bis-tris-d19, pH 
6.8, at 283K.
Peptides
Zinc binding
C, 
mM
DLS Turbidityc OD350 × 102/OD405 × 102
Ka × 104, M−1 Na Ref
Diameter, 
nmb Free peptide Peptide + ZnCl2
Aβ 1–16
1.70 ± 0.40 1.0 ITC 43 0.2 0 2.2 ± 1.3/2.2 ± 1.8 3.0 ± 1.7/1.8 ± 0.9
5.0 2.5 ± 0.3 9.4 ± 1.7/5.4 ± 1.1 44 ± 10/38 ± 10
H6R-Aβ 1–16 0.24 ± 0.03 0.5 ITC36 1.0 0 1.5 ± 0.6/1.7 ± 0.9 2.0 ± 1.2/1.9 ± 1.3
isoD7-Aβ 1–16 1.30 ± 0.40 1.0 ITC 43 0.8 2.7 ± 0.3 2.4 ± 1.1/2.4 ± 1.1 491 ± 232/454 ± 219
Aβ 6–16 1.27 ± 0.13 1.0 this work, ITC 2.0 17 ± 6 2.0 ± 0.8/2.2 ± 0.8 422 ± 20/278 ± 11
isoD7-H13R-Aβ 1–16 0.14 ± 0.01 1.0 this work, NMR 1.0 0 1.7 ± 1.1/1.4 ± 1.0 2.0 ± 1.3/2.0 ± 1.1
isoD7-Aβ 1–10 0.12 ± 0.01 1.0 this work, NMR 1.0 0 2.6 ± 1.4/2.5 ± 1.1 2.8 ± 1.7/2.8 ± 1.3
Table 1.  Parameters of zinc binding to the peptides measured by ITC or NMR, mean diameter of 
oligomers in the absence and presence of twofold molar excess of ZnCl2 measured by dynamic light 
scattering, and turbidity of the solutions. Concentration of the peptides in DLS and turbidity measurements 
are shown. aN – stoichiometry. bMean diameter of oligomers determined by DLS. cOD350 and OD405 – optical 
density of the peptide solutions measured at 350 nm and 405 nm.
www.nature.com/scientificreports/
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Zinc-induced dimers of Аβ1–16, Аβ6–16, H6R-Аβ1–16 and isoD7-Аβ1–16 have common 
zinc-mediated dimerization interface. We previously showed by a combination of NMR, isothermal 
titration calorimetry (ITC) and surface plasmon resonance methods that a stable dimeric form of the peptide 
H6R-Аβ 1–16 is formed when bound to a zinc ion36. Residues E11 and H14 of the two peptide subunits formed 
Figure 3. Fragments of 1D spectra of Аβ 1–16 (A), H6R-Аβ 1–16 (B), and AcisoD7-Аβ 1–16 (C) in the presence 
of half molar equivalence of Zn2+. Peptide concentration is ~0.2 mM. Spectra were recorded at 283K in 90% 
H2O/10% D2O in the presence of 10 mM bis-Trid-d19 buffer, pH 6.8 at 283K. Characteristic signal at ~0.2 
ppm belongs to the methyl group Hγ 1* of V12 in dimeric complex. Content of the dimer at ~0.2 mM total 
concentration of the peptides is about 5%.
Figure 4. Fragment of the ROESY spectrum (mixing time 100 ms) of the AcH6R-Аβ1–16 in the presence of 
half molar equivalence of Zn2+ recorded at 283 K in D2O in the presence of 10 mM bis-Trid-d19 buffer, pH 
6.8. The peptide concentration ~2.5 mM. Cross-peaks with positive intensity (red) correspond to the exchange 
signals between monomer and dimer. Negative (blue) cross-peaks correspond to NOE correlations.
www.nature.com/scientificreports/
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the dimerization interface in this complex. For the dimeric form of H6R-Аβ 1–16 a set of characteristic signals was 
observed in NMR spectra, including marked resonances of the methyl group Hγ 1* of V12 (~0.2 ppm) and amide 
proton of H14 (~9.5 ppm). The intensity of these signals made it possible to evaluate the dimer ratio, which is 
dependent on the total peptide concentration and varied between 1–3% for the diluted solutions and 35–40% for 
the solutions of H6R-Аβ 1–16 at the peptide concentration of 5–8 mM.
A comparison of the NMR spectra of the peptides Аβ 1–16, Аβ 6–16, H6R-Аβ 1–16 and isoD7-Аβ 1–16 in the pres-
ence of zinc ions obtained in this study has shown a set of characteristic signals similar to that observed in the 
work cited above, for all these peptides (Fig. 3, S3, S8). At low concentration of the peptides Аβ 1–16, H6R-Аβ 1–16 
and isoD7-Аβ 1–16 (~0.2 mM) fraction of the dimeric form is nearly identical (Fig. 3). Fraction of the dimeric 
forms rises with concentration of the peptides as expected for any dimerization process. Such tendency has been 
shown for H6R-Аβ 1–1636, which has the highest dimer abundance among the studied peptides. The common set 
of characteristic signals found for the dimers of Аβ 1–16, Аβ 6–16, H6R-Аβ 1–16 and isoD7-Аβ 1–16 indicates that all the 
dimers have the same zinc-induced dimerization interface, namely, 11EVHH14.
Equilibrium between zinc-bound monomers and dimers of Аβ1–16 isoforms. Equilibrium between 
free peptide and its zinc-bound monomer complex is fast on the NMR time scale. In contrast, equilibrium 
between zinc-bound monomers and dimers is slow on the NMR time scale, as evidenced by the two separate sets 
of NMR signals (Fig. 3, 4, S2,S3,S8). The exchange between monomers and dimers is unambiguously confirmed 
by the rotating frame nuclear Overhauser effect spectroscopy (ROESY) since cross-peaks originating from the 
through-space dipole-dipole interaction (NOE) have opposite signs to the cross-peaks derived from chemical 
exchange. Figure 4 illustrates NOEs between S8 Hα and Hβ protons (negative, blue), and exchange cross peaks 
between several Hα signals of monomeric and dimeric forms (red, positive). Exchange between zinc-bound 
monomers and dimers of H6R-Аβ 1–16 and isoD7-Аβ 1–16 is also confirmed by characteristic cross-peaks in the 
NOESY spectra (Fig. S8) demonstrating exchange between V12 Hγ 1* signals. Both peptides show identical pat-
terns of NMR signals and differ only by fraction of the dimeric forms.
Rate constants km → d and kd → m at equilibrium between the monomeric and dimeric complexes of H6R-Аβ 1–16 
with Zn2+ have been measured using the magnetization transfer NMR experiments (see Supporting information 
pp. S24-S28 for details). It has been found that an effective rate constant km→d measured at the total peptide con-
centration of 2.3 mM in the presence of half molar equivalence of ZnCl2 equals to 8.6 ± 0.6 s−1 and kd→m equals 
to 31.3 ± 2.3 s−1.
Structure of zinc-mediated H6R-Аβ1–16 dimer in solution. Significant ratio of stable (on NMR time 
scale) zinc-bound H6R-Аβ 1–16 dimers allowed to determine the dimer structure in solution. The NMR structure 
has been determined using the set of distance restraints collected from 2D NOESY and ROESY spectra and a set 
of constraints between zinc ion and residues E11 and H14 (Table 2). In addition to NOEs between the signals 
of the dimer, NOEs between the signals of zinc-bound monomer have been also included in the list of distance 
restraints used for structure calculation (Table 2). Due to the equilibrium between zinc-bound monomer and 
dimer, more intensive signals of monomer (Fig. 5) contain all the information about interatomic distances within 
the dimer via the transferred NOE mechanism. Similar transferred NOE mechanism is observed in the equilib-
rium between free peptide and its complex with a larger protein49. Effectiveness of such mechanism is determined 
by the substantially more effective cross-relaxation in dimer due to its slower molecular tumbling.
QM/MM calculations have been carried out to determine the restraints that describe geometry of the 
zinc-mediated interface formed by pairs of E11 and H14 from the interacting subunits. An approach similar to 
that described earlier for the determination of NMR structure of rat Аβ 1–16 complex with zinc ions47 has been used 
in the calculations. Tetrahedral geometry of the zinc ion coordination sphere originated from quantum mechan-
ics calculations (Fig. S12B). Such geometry is in good agreement with the principles governing Zn binding in 
proteins50 and in agreement with the previously determined structures of Аβ 1–16 zinc-bound complexes11,17,34,47.
Number of NOE restrains 181
 Intra-residue 91
 Sequential 55
 Medium-range 23
 Long-range (|i-j| > 4) 4
 Distance constraints of Zn2+ chelating center 8
Ramachandran map statistics
 % of residues in most favorable region of Ramachandran map 73.5
 % of residues in disallowed region of Ramachandran map 0.0
NMR family statistics
 Number of conformers in family of structure 20
 Number of distance violations (> 0.5 Å) per structure < 1
 Backbone (C, Cα and N) rmsd of residues 1–16 (Å) 2.31 ± 0.55
 Backbone (C, Cα and N) rmsd of residues 6 – 15 (Å) 1.39 ± 0.36
 Backbone (C, Cα and N) rmsd of residues 8 – 15 and all heavy atoms of residues 11 and 14 (Å) 1.08 ± 0.26
Table 2.  NMR restrains and structural statistics for the complex of two H6R-Aβ1–16 peptides with zinc ion.
www.nature.com/scientificreports/
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Single set of zinc-bound dimer chemical shifts indicates that dimer subunits are chemically equivalent. 
Therefore, each NOE has been assumed to represent either intra-chain correlation or correlation between two 
adjacent subunits. All NOEs have been treated in the structure calculations as ambiguous distance restraints 
allowing optimization protocol to find optimal assignments.
A family of 20 NMR structures has been determined on the basis of 181 experimental restraints (see Table 1 
for details) using simulated annealing MD protocol in explicit water environment51. For most of the residues, the 
number of NOEs per residue is between 15 and 40 (Fig. S9). Statistics of the final ensemble are given in Table 1 
and superposition of the final family of calculated structures is presented in Fig. S10. A representative structure 
was selected from the ensemble of calculated structures as being the one that is closest to all the other structures 
and thus gives the lowest sum of pairwise RMSD for the remainder of the structures in the family. RMSD between 
the family of calculated structures and the representative structure is about 2.3 Å for the backbone heavy atoms. 
RMSD between the structures in the final family for heavy atoms of the dimerization interface core (residues 
8–15) is about 1.0 Å (Table 1). On Ramachandran plot (Fig. S11), 73.5% of the residues in the whole NMR family 
are in the most favored regions and none in the disallowed regions. Representative structure has been additionally 
optimized using the QM/MM method in order to refine the geometry of Zn2+ environment (Figs 6 and S12).
Figure 5. Fragment of the NOESY spectrum (mixing time 250 ms) of the AcH6R-Аβ1–16 in the presence of 
half molar equivalence of Zn2+ recorded at 274 K in 90%H2O/10%D2O, 10 mM bis-Trid-d19 buffer, pH 6.8. 
The peptide concentration ~2.5 mM. Red arrows show sequential assignment pathway in the region of HN–
Hα correlations. Blue lines indicate resonances of the representative signals of the dimer complex, green lines 
correspond to the signals of the monomeric zinc-peptide complex.
www.nature.com/scientificreports/
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Identification of the second zinc-dependent dimerization interface within Аβ1–16, Аβ6–16 and 
isoD7-Аβ1–16. Peptides H6R-Аβ 1–16, Аβ 1–16, isoD7-Аβ 1–16 and Аβ 6–16 have identical primary zinc-mediated 
homodimerization interface, which shows characteristic resonances, such as Hγ 1* of V12 (Figs 3 and S3, S8). 
In the interface, pairs of residues E11 and H14 of the interacting subunits coordinate a common zinc ion. In the 
presence of equimolar amounts of zinc ions only H6R-Аβ 1–16 does not precipitate up to 10 mM, whereas the other 
peptides rapidly precipitate when their concentration reaches threshold values (> 5 mM for Аβ 1–16, > 0.2 mM for 
isoD7-Аβ 1–16, > 0.8 mM for Аβ 6–16) (Table 1). Apparently, precipitation can occur only if an oligomer subunit 
possesses at least two sites that sterically can be involved in the formation of zinc-mediated interfaces with other 
peptide subunits. Accordingly, the Аβ 1–16, Аβ 6–16 and isoD7-Аβ 1–16 peptides must have a second dimerization 
interface located within the Аβ minimal zinc binding site 6–1434. The fact that aggregation of H6R-Аβ 1–16 is not 
observed at any peptide concentration as shown in Table 1, clearly indicates the involvement of residue H6 in the 
second zinc-dependent interface. Considering that side chains of residues Asp, Glu и His are typical zinc chelators 
and E11 и H14 are part of the primary dimerization interface, one can rationally assume that the second dimeri-
zation interface should include residues D7 (isoD7) or H13 in addition to H6.
To probe involvement of isoD7 in the second dimerization interface we have studied a capacity of the model 
peptide isoD7-Аβ 1–10 to form dimers in the presence of zinc ions. We have performed NMR titration experi-
ments using the method of continuous variations36,38,52. The results show that stoichiometry of interaction of 
isoD7-Аβ 1–10 with Zn2+ is 1:1 (Fig. S13B, Table 1). The coordination centers of zinc ion in the monomeric com-
plex with isoD7-Аβ 1–10 have been identified from changes of the chemical shifts between free and zinc-bound 
states (Fig. S14, Tables S5, S6) . In addition to imidazole ring of H6, Zn2+ is coordinated by the side chain carboxyl 
group of isoD7 and two backbone carbonyl groups of the residues F4 and H6. Chemical shift changes data (Fig. 
S15) allowed to calculate the binding constant of Zn2+ to isoD7-Аβ 1–10, Ka = 1.19 ± 0.06·103 M−1 (Fig. S13A, 
Table 1). The data show that the peptide forms a monomeric complex with zinc ion and thus isoD7 is not involved 
in the second dimerization interface.
Similarly, to probe involvement of residue H13 in the second dimerization interface we have studied the model 
peptide isoD7-H13R-Аβ 1–16. The H13R substitution has been designed to minimize changes in the peptide prop-
erties relative to isoD7-Аβ 1–16. Chemical shifts of the peptide in the presence and absence of zinc ions are given 
in Supplementary material (Tables S3 and S4 ). NMR studies of the interaction of isoD7-H13R-Аβ 1–16 with Zn2+ 
(Fig. S16) have shown zinc binding constant Ka = 1.35 ± 0.06·103 M−1 (Fig. S17A, Table 1) and stoichiometry 
(1:1) (Fig. S17B, Table 1). Zinc-induced chemical shift changes (Fig. S18) indicate that side chains of the two 
histidine residues (H6 and H14) are involved in the coordination of Zn2+. Chemical shifts of E11 do not change 
upon interaction of the peptide with Zn2+, suggesting that this residue is not involved in its coordination. RMSD 
of the 1H and 13C chemical shifts between the free and zinc-bound peptides (Fig. S18) indicate that zinc ion is 
coordinated by backbone carbonyl groups of the residues H6 and R5, similarly to that observed earlier in the S8 
phophorylated Aβ 1–16 peptide38.
Taken together, the described data show that in zinc-induced oligomers of the Аβ 1–16, Аβ 6–16 and isoD7-Аβ 1–16 
peptides each subunit interacts with the adjacent subunits via residues E11 and H14 from the primary dimeriza-
tion interface, and residues H6 and H13 from the second one.
The origins of higher oligomerization propensity of isoD7-Аβ1–16 and Аβ6–16 compared to Аβ1–16. 
Our experimental results indicate that isomerization of D7 as well as truncation of the first five residues facili-
tate formation of the second Zn-dependent interaction site. To understand why a relatively small change of the 
peptide structure between Аβ 1–16 and isoD7-Аβ 1–16 causes dramatic change in their zinc-induced oligomeriza-
tion, MD simulations have been performed for homodimer Aβ 1–16·Aβ 1–16 and heterodimer Aβ 1–16·isoD7-Aβ 1–16. 
Conformational behavior of Aβ 1–16 and isoD7-Aβ 1–16 chains in the respective homodimer and heterodimer, has 
Figure 6. Structure of the representative conformer H6R-Aβ1–16 zinc-bound dimer after additional QM/MM 
refinement. Shown are backbone atoms of two polypeptide chains and side chains of the residues 10–14 involved 
in formation of zinc-induced dimerization interface. Solvent-accessible molecular surface is calculated for all 
atoms and colored according to the interpolated charge distribution.
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been examined in MD trajectories. In the MD simulations the primary zinc-dependent interface structure has 
been kept in its initial conformation, and distances between the imidazole rings of residues H6 and H13 in the 
second interface in both Aβ 1–16 and isoD7-Aβ 1–16 chains have been constrained in order to keep them close 
enough for zinc ion coordination.
MD simulations have shown that residues D7 and S8 in the Aβ 1–16 chain form a stable bend (RMSD over 
N, C and Cα atoms of residues 7 and 8 was 0.13 Å). Such bend is stabilized by hydrogen bond between the D7 
side-chain carboxyl and S8 side-chain hydroxyl (Fig. 7a). In contrast, in the isoD7-Aβ 1–16 chain residues D7 and 
S8 do not form a bend, but demonstrate a propensity to form extended conformation (Fig. 7b). Thus, structural 
changes associated with the isomerization of D7 (elongation of the peptide backbone by one additional CH2 
group and reduction of the side-chain) lead to disruption of the interaction between residues D7 and S8.
MD results show that in both peptides Аβ 1–16 and isoD7-Аβ 1–16, residues H6 and H13 adopt a conformation 
supporting interaction with Zn2+. However, probability to adopt the most favorable conformation is higher for 
the isoD7-Аβ 1–16 peptide. On the contrary, such conformational space in Аβ 1–16 peptide is restricted due to the 
bent region 7–8 (Fig. S19). Thus, isomerization of D7 increases capacity of the residues H6 and H13 to form 
the second zinc-dependent interface interaction with zinc ion, which facilitates oligomerization of the peptide. 
Truncation of the first five residues of Аβ 1–16 forms the Аβ 6–16 peptide with increased conformational freedom of 
the N-terminal residue H6 and similarly facilitates zinc-induced oligomerization.
Discussion
In human tissues, Aβ is a group of peptides, heterogenous at their N-termini and/or C-termini and produced 
by the β - and γ -secretase-dependent cleavage of amyloid precursor protein53. Structural characterization of the 
full lenght Aβ monomer in solution is difficult due to the tendency of the peptide to aggregate. It was found 
that the soluble Aβ 1–42 peptide is an intrinsically disordered polypeptide in aqueous solution, having β -strand 
secondary structure within the segments 2–7, 16–23, 28–32, and 34–3654. Solid-state NMR spectroscopy and 
electron microscopy allowed to identify diverse morphologies and structures in Aβ fibrils (reviewed in55,56). The 
metal-binding domain 1–16 was found to be flexible, situated outside of the hydrophobic core formed by the 
residues 17–4220,57. It is worth noting that the absence of this domain in the so called p3 peptide, which comprises 
the Aβ region 17–42, prevents the formation of oligomers57,58. Another fact that three amino acid substitutions 
that discern Aβ of rats and mice from all other mammals and protect rodents against AD are situated within the 
metal binding domain, indicating its involvement in initialization of the pathological Aβ aggregation. Several 
AD-causing mutations are also located in the metal binding domain of Aβ 59,60. A role of Aβ 1–16 in the AD pathol-
ogy is that it is required for the formation of zinc-induced oligomers. Antibodies targeting the N-terminal region 
of Aβ are able to block the formation of Aβ 40 amyloids61, thus suggesting that the N-terminal domain contributes 
to the formation and/or the maturation of Aβ fibrils.
Our results indicate that conformation of the 10–15 region of the metal binding domain in absence of zinc 
ions is identical in all studied variants of Aβ 1–16, and that it is likely to be pre-formed for an effective zinc ion trap-
ping. The region 11–14 was shown to play a principle role in Zn2+ binding in the monomeric complex17,34. Such 
interaction includes two consecutive steps, (i) primary zinc ion binding by side chains of the residues E11, H13, 
H14 and a water molecule, (ii) substitution of water by the residue H6 due to movement of the fragments 1–8 and 
11–14 towards each other.
Figure 7. Final conformations from the 20 ns restrained molecular dynamic trajectories of the dimers 
(A) Aβ 1–16·Aβ 1–16 and (B) isoD7-Aβ 1–16·Aβ 1–16. Restraint of 6 Å has been applied to the distance between 
H6 Nε 2 and H13 Nε 2 atoms during MD simulations in order to keep positions of imidazole rings in 
conformation favorable for zinc binding. Residues H6, D7, isoD7, S8 and H13 are shown by bold sticks.
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It was suggested that a zinc ion binds to monomeric Aβ and then the zinc-peptide complex undergoes confor-
mational changes that lead to the formation in the formation of zinc-induced Aβ oligomers11,21,62,63. The role of 
11EVHH14 fragment in the formation of Aβ dimers was reported previously11,36–38,64. In the current study we have 
established the three-dimensional structure of a zinc-linked dimer of H6R-Аβ 1–16, with the dimerization interface 
formed by the side chains of residues E11 and H14. Residues 10–15 also contribute to structure stabilization by 
hydrophobic interactions between Y10 and V12, and by forming hydrogen bonds between the HN protons of 
H14 and Gln15 and the backbone carbonyl groups of E11 and V12 respectively (Fig. 6, Fig. S12). Low field shifts 
of these two amide protons are in agreement with this conclusion. Characteristic high field shift of the resonance 
of Hγ 1*of V12 originates from its proximity to the aromatic ring of Y10 in the hydrophobic core and additionally 
validates the structure. Thus, binding of a zinc ion to the 11EVHH14 fragment leads to formation of the peptide 
dimer where one zinc ion is coordinated by the residues E11 and H14 from the two interacting peptide chains.
Miller et al.62 discuss two possible scenarios of the zinc-induced amyloidogenesis. In the first one, metal ions 
bind amyloid monomers and induce their assembly into oligomers via interactions of the zinc-bound complexes. 
Alternative mechanism presumes that metal ions bind to pre-formed apo-oligomers of Aβ . Lim et al.13 showed 
that zinc binding to Aβ initiates a cascade of conformational changes leading to intermolecular interactions of Aβ 
via residues 12–21. After an initial structure rearrangement caused by zinc binding, the C-terminal residues read-
just their conformation to support effective intermolecular interaction18,21,47,57–59,61,65. Similar structural changes 
of the metal-free Aβ 1–40 peptides were also observed in the presence of the preformed oligomers13, suggesting 
that such conformational transitions may constitute a general molecular mechanism of the Aβ amyloidogenesis.
We have shown here for Aβ 1–16 and isoD7-Aβ 1–16 that formation of the primary zinc-dependent dimerization 
interface by residues E11 and H14 initiates conformational rearrangement leading to formation of the second 
dimerization interface by residues H6 and H13 (Fig. 7). Emergence of this second interface is a key event enabling 
zinc-induced oligomerization of the metal binding domain (Fig. 8).
If a zinc-induced dimer is formed by native Aβ 1–16 via primary interface, it restricts conformational mobility 
of the peptide. We hypothesize that this can result in disruption of the reciprocal aligning of residues 6 and 13 
necessary to form the second interface, leading to lower fraction of peptides with both interfaces (Fig. S19). This 
explains moderate susceptibility of the native peptide Aβ 1–16 to oligomerization (Aβ 1–16 precipitates at concen-
trations > 5 mM, Table 1). In comparison with Aβ 1–16, isoD7-Aβ 1–16 undergoes oligomerization at substantially 
higher rate (isoD7-Aβ 1–16 precipitates at concentrations > 0.3 mM). Isomerization of D7 considerably increases 
conformational space of the peptide backbone and facilitates favorable aligning of the side chains of residues H6 
and H13 that form the second dimerization interface. Another way to increase conformational freedom of the 
H6 side chain is to remove the first five residues of Aβ , including residues E1 and D3 capable of electrostatically 
interacting with H634. Indeed, peptide Aβ 6–16 precipitates at ~0.8 mM (Table 1). Notably, enzymatic removal of the 
first five Aβ residues is performed by ACE66 as we showed earlier, which can potentially link ACE to Alzheimer’s 
disease.
The results obtained in this study allow to propose the molecular mechanism of zinc-dependent oligomeriza-
tion of Aβ metal binding domain (Fig. 8). Oligomerization starts with formation of zinc-peptide monomeric com-
plex (Fig. 8b), and subsequent transformation of the complex to a dimer (Fig. 8c), where zinc ion is coordinated 
by the side chains of residues E11 and H14 from the interacting peptide molecules. After this, conformational 
rearrangement in the segments 6–14 of each subunit leads to formation of the second zinc-dependent dimeri-
zation interface composed of residues H6 and H13. The dimer becomes a seed of subsequent zinc-dependent 
oligomerization leading to formation of higher order soluble oligomers that are transformed into insoluble aggre-
gates (Fig. 8d). In contrast with the earlier concepts of polymorphism of Aβ within zinc-dependent oligomers, our 
data suggest that the Aβ metal binding domain has a distinct three-dimensional structure, allowing the domain 
to simultaneously interact with two other Aβ molecules. This could trigger a “chain reaction” of zinc-induced 
Aβ oligomerization. This mechanism is in line with our recent in vivo studies showing that synthetic peptides 
Figure 8. Cartoon representation of the zinc-induced oligomerization of the Aβ metal binding domain. 
Tubes represent Aβ 1–16, isoD7-Aβ 1–16 and Aβ 6–16 fragments. Zinc ions are shown as gray circles. Shown are 
stages of oligomerization: (a) peptide in free state, (b) peptide in complex with zinc ion, (c) zinc-induced 
peptide dimer, and (d) zinc-induced peptide oligomer formed around the dimer. Oligomerization seed (peptide 
dimer) is highlighted by pink.
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specifically binding the Aβ 11EVHH14 region and preventing zinc-induced Aβ dimerization, significantly reduce 
progression of cerebral amyloidosis in transgenic mice67.
Conclusions
We have demonstrated that in the Aβ metal binding domains of intact, H6R mutant and the isoD7 Aβ isoforms 
in the absence and presence of zinc ions, the dominant backbone conformation of the fragment 10–15 is iden-
tical. This fragment forms primary zinc-mediated dimerization interface of all studied metal binding domains. 
Solution structure of zinc-mediated H6R-Аβ 1–16 dimer has been determined, providing insight into the mecha-
nism of formation of the dimerization interface. Zinc-induced oligomerization of synthetic peptides representing 
the 1–16 metal binding domains of natural Аβ variants has been shown to follow the same molecular mechanism: 
(i) peptide dimer is formed through the primary zinc-mediated interface 11EVHH14; (ii) residues H6 and H13 are 
realigned creating the second zinc-dependent interface in each subunit; (iii) the dimer becomes a seed of subse-
quent zinc-dependent oligomerization of Aβ 1–16. Our results indicate that the extent of conformational freedom 
of residue H6 determines the propensity of Aβ 1–16 isoforms to undergo zinc-induced oligomerization. Targeting 
of Aβ zinc-mediated interfaces may provide a therapeutic route for AD treatment.
Methods
Materials. All chemicals and solvents were of HPLC-grade or better and were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Synthetic peptides (purity > 98% checked by RP-HPLC) Аβ 1–16 
(DAEFRHDSGYEVHHQK), Аβ 6–16 (HDSGYEVHHQK), H6R-Аβ 1–16 (DAEFRRDSGYEVHHQK), isoD7-Аβ 1–16 
(DAEFRH[isoD]SGYEVHHQK, where [isoD] - isoaspartate), isoD7-H13R-Аβ 1–16 (DAEFRH[isoD]
SGYEVRHQK, and isoD7-Аβ 1–10 (DAEFRH[isoD]SGY) were purchased from Biopeptide Co., LLC (San Diego, 
CA, USA). C-termini of all the peptides were protected with amide group. N-termini of Аβ 1–16 and H6R-Аβ 1–16 
were either unprotected or protected with acetyl. N-terminus of Аβ 6–16, isoD7-Аβ 1–16, isoD7-H13R-Аβ 1–16 and 
isoD7-Аβ 1–10 were protected with acetyl group. The lyophilized peptides were dissolved in buffer before each 
experiment. Concentration of the peptides was determined by UV absorption spectroscopy using spectropho-
tometer Cary50 (Varian) and the extinction coefficient of 1280 M−1 cm−1 at 280 nm (from Tyr 10 of Aβ ). Zinc 
chloride (99.99%, ACROS Organics) prior to the weighing was dried out during 1–2 hours at 150 °C.
Dynamic light scattering. Dynamic light scattering (DLS) measurements were carried out on a Zetasizer 
Nano ZS apparatus (Malvern Instruments Ltd., UK) in accordance with the manufacturer instruction. The 120-μ L 
aliquots of peptide solutions were placed into a BRAND UV microcuvetter (BRAND GMBH, Germany) and used 
for the measurements. Measurements of peptides in the presence of Zn2+ were carried out within 10 minutes after 
addition of two-fold molar excess of ZnCl2 to the peptide solutions. The instrument is equipped with a He-Ne 
laser source (λ = 632.8 nm) and operates in the back-scatting mode, measuring particle size in the range between 
0.6 nm and 10 μ m. Particle size distribution was estimated using a CONTIN data analysis utility with spherical 
approximation of the particles, available as a part of the instrument software.
Turbidity measurements. Measurements were performed on a NanoDrop 1000 spectrophotometer 
(Thermo Scientific, USA). The optical density of peptide solutions was measured at 350 nm and 405 nm, using 
2 μ L aliquots of the peptide solutions. Measurements of peptides in the presence of Zn2+ were carried out after 
30–40 minutes following addition of ZnCl2 to the peptide solutions.s.
Isothermal titration calorimetry (ITC). The thermodynamic parameters of zinc binding to Aβ 6–16 were 
measured using a MicroCal iTC200 System (GE Healthcare Life Sciences, USA) as described previously36,43,47. 
Experiments were carried out at 25 °C in 50 mM Tris buffer, pH 7.3. 2 μ L aliquots of the ZnCl2 solution were 
injected into the 0.2 mL cell containing the peptide solution to obtain a complete binding isotherm. The titration 
curves were fitted using MicroCal Origin software. Association constant (Ka), binding stoichiometry and enthalpy 
were determined by a non-linear regression fitting procedure (Fig. S20).
NMR experiments. Peptides in the concentration of 0.2–2 mM were dissolved in 10–20 mM bis-Tris-d19 
(2,2-Bis(hydroxymethyl)-2,2′ ,2″ -nitrilotriethanol-d19 with 98% 2D enrichment) buffer solution (pH 6.8). Sodium 
salt of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid in the concentration of 10–40 μ M was added as a standard. 
NMR spectra were measured in the temperature range between 274 K and 308 K either in D2O or in 90% 
H2O/10% D2O on a Bruker AVANCE 600 MHz spectrometer equipped with a triple resonance (1H, 13C and 15N) 
pulsed field z gradient probe or on a Varian INOVA 600 MHz spectrometer equipped with a triple resonance (1H, 
13C and 15N) cryoprobe. 1D NMR spectra were processed and analyzed using the Mnova software (Mestrelab 
Research, Spain). 2D NMR spectra were processed by NMRPipe68 and analyzed using SPARKY69.
NMR signal assignment. The 1H, 15N and 13C signal assignments of isoD7-Аβ 1–10, isoD7-Аβ 1–16, 
isoD7-H13R-Аβ 1–16 and Аβ 6–16 peptides in free form and in complex with zinc ions were obtained using the 
following 2D spectra: DQF-COSY, TOCSY (mixing time of 70 and 80 ms), NOESY (mixing time of 200, 225, 250 
and 300 ms), 13C-1H HSQC and 15N-1H HSQC. Heteronuclear experiments were measured at the natural abun-
dance of the 13C and 15N isotopes (Fig. S1–S4). Chemical shifts are presented in the supporting material (Tables 
S1–S7).
NMR titration experiments. To identify the amino acid residues that coordinate zinc ion in the peptides 
isoD7-Аβ 1–10 and isoD7-H13R-Аβ 1–16, and for determining association constants of zinc ions NMR titration 
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experiments were carried out. Peptides at concentration of 1.0–1.5 mM at pH 6.8–7.0 were titrated with a solution 
of ZnCl2 in a buffer of identical composition at the same pH value. 1D spectra were recorded for each titration 
point. Figures S15 and S16 show changes of the chemical shifts with increasing molar content of [Zn2+] from 
0.05 to 10.0 relatively to the peptide concentration. The volume of solution at the final point increased from 600 
to 800 μ L. Chemical shift changes of the representative signals in titration experiments were used for calculation 
of the Ka values (Figs S13A and S17A). The linear nature of Δ δ values Δ δ presented in Scatchard coordinates52 
confirms equilibrium between the free and zinc-bound peptide forms.
Method of continuous variations52 was used to determine stoichiometry of zinc binding to the peptides 
isoD7-Аβ 1–10 and isoD7-H13R-Аβ 1–16. This involved preparation of a series of samples containing both the pep-
tide and ZnCl2 in varying proportions of the components, but in a fixed total concentration (from 1.0 to 1.7 mM). 
Changes of the chemical shifts induced by the interaction of the peptide with zinc ions were analyzed. The plots of 
the product Δ δ ·[P]0 (Δ δ – change of the chemical shift; [P]0 – total peptide concentration in the sample) versus 
the mole fraction of [Zn2+] show maximum at the fraction value, which corresponds to the stoichiometry (Figs 
S13B and S17B).
Magnetization transfer experiments. In order to measure exchange rates between monomeric and 
dimeric states of the Zn·H6R-Аβ 1–16 complex, magnetization transfer NMR technique was used. Magnetization 
transfer experiments involved selective excitation of the signal at 0.9 ppm, which belongs to the methyl group 
Hγ 1* of V12 in the monomeric form of zinc-peptide complex, with subsequent detection of the intensity of the 
signal at 0.2 ppm, which belongs to the same group in the dimeric form. Series of experiments with varying delays 
between the inverting and reading pulses were carried out. All the experimental details and data analysis are pro-
vided in the supplementary material (pages S24-S28).
NMR restrains. NOE distance restraints used in structure calculation of the dimeric form of Zn-H6R-Аβ 1–16 
complex were obtained from 2D NOESY spectra acquired at 274 K in H2O or at 278 K in D2O. NMR signal assign-
ment of Zn···H6R-Аβ 1–16 complex was reported earlier36. Representative fragment of the NOESY spectrum with 
some principal assignments is shown on Fig. 5. Signal intensities in NOESY spectra were calibrated and converted 
into the distance restrains using the fixed distance intraresidue NOEs as the reference. Distance and torsion angle 
restraints representing the coordination site of zinc ion were obtained using the quantum mechanical calculations 
(see below).
QM/MM and restrained molecular dynamics. Structures of the complex of H6R-Аβ 1–16 with zinc 
ions were determined using the GROMACS 3.3.1 software70, AMBER 03 force field71 and optimized protocol 
of the simulated annealing MD calculations47,51 with the set of distance restraints listed in Table 2. QM/MM 
Car–Parrinello simulation approach72,73 was applied to optimize the zinc binding site and to obtain restrains that 
describe geometry of Zn2+ coordination center. All the parameters and protocols of the MD and QM/MM calcu-
lations were described earlier in detail47. Convergence of the calculations was determined using root mean square 
deviation (RMSD) of the coordinates of the C, Cα , and N atoms of protein backbone, calculated for the whole 
family of structures. Quality of the calculated structures was defined on the basis of the percent of hits of the 
main dihedral angles ϕ and ψ in the most favorable and prohibited areas of Ramachandran map using Procheck_
NMR74. Structures were visualized and analyzed using the InsightII or Discovery Studio software (Accelrys Inc.).
MD simulations. Molecular modeling has been performed for homodimer Aβ 1–16·Aβ 1–16 and heterodi-
mer Aβ 1–16·isoD7-Aβ 1–16 using the representative NMR conformer of the H6R-Aβ 1–16 dimer as initial structure. 
Homology modeling was performed using the Chimera software75. Partial charges for the non-standard residue 
isoD7 were assigned using the AM1-BCC method76. Initial models were refined using the restrained molecular 
dynamic simulation with GROMACS 4.6.5 software70 and Amber99SB-ILDN force field77. Peptide dimers were 
placed in the cubic cell with a minimum distance (0.8 nm) between a protein and the box wall and soaked with 
TIP3P water molecules78. Total charge of the solution has been neutralized with sodium ions. Energy was min-
imized using the steepest descent algorithm and the system was further equilibrated during 100 ps of constant 
volume (NVT) molecular dynamic simulation followed by 100 ps of constant pressure (NPT) molecular dynam-
ics. 10 ns MD simulations were carried out using the NPT ensemble to relax protein chains. 6 Å restraint has been 
applied to the distance between H6 Nε 2 and H13 Nε 2 atoms. 20 ns NPT MD simulations were performed to fol-
low approaching of imidazole rings of H6 and H13. Position of the side chains of residues E11 and H14 together 
with the coordinated zinc ion were restrained during all simulation steps. Calculations were performed at 300 K, 
pressure 1 bar, with a 2 fs integration step using Berendsen barostat and velocity rescale method for thermostat. 
Particle-mesh Ewald method79 has been implemented to treat long-range electrostatic interactions, and LINCS 
algorithm to control the lengths of covalent bonds80.
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